Prospective multicenter trial: Hormonal changes by switching from GnRH agonist to GnRH antagonist in patients with early stage of castration resistant prostate cancer as a second line hormonal therapy.

Hiroji Uemura,Yumiko Yokomizo,Masahiro Yao,Narihiko Hayashi,Kazuki Kobayashi,Jun-ichi Ohta,Kazuo Kitami,Takeshi Kishida,Akitoshi Takizawa

Prospective multicenter trial: Hormonal changes by switching from GnRH agonist to GnRH antagonist in patients with early stage of castration resistant prostate cancer as a second line hormonal therapy.

2018

Hiroji Uemura
Yumiko Yokomizo
Masahiro Yao
Narihiko Hayashi
Kazuki Kobayashi
Jun-ichi Ohta
Kazuo Kitami
Takeshi Kishida
Akitoshi Takizawa

e17030Background: It was reported that GnRH antagonist could extend progression free survival for prostate cancer patients significantly longer than GnRH agonist in a first line hormonal therapy. H...

Keywords:

Multicenter trial
Hormone
Oncology
Prostate cancer
Hormonal therapy
Pathology
Castration
Agonist
Medicine
GnRH Antagonist
Internal medicine
second line
Progression-free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations